Abstract
We conducted a SNP-based genome-wide association study (GWAS) focused on the high-risk subset of neuroblastoma1. As our previous unbiased GWAS showed strong association of common 6p22 SNP alleles with aggressive neuroblastoma2, we restricted our analysis here to 397 high-risk cases compared to 2,043 controls. We detected new significant association of six SNPs at 2q35 within the BARD1 locus (Pallelic = 2.35 × 10−9–2.25 × 10−8). We confirmed each SNP association in a second series of 189 high-risk cases and 1,178 controls (Pallelic = 7.90 × 10−7–2.77 × 10−4). We also tested the two most significant SNPs (rs6435862, rs3768716) in two additional independent high-risk neuroblastoma case series, yielding combined allelic odds ratios of 1.68 each (P = 8.65 × 10−18 and 2.74 × 10−16, respectively). We also found significant association with known BARD1 nonsynonymous SNPs. These data show that common variation in BARD1 contributes to the etiology of the aggressive and most clinically relevant subset of human neuroblastoma.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
p50 mono-ubiquitination and interaction with BARD1 regulates cell cycle progression and maintains genome stability
Nature Communications Open Access 06 October 2020
-
HIF-1 transcription activity: HIF1A driven response in normoxia and in hypoxia
BMC Medical Genetics Open Access 26 February 2019
-
PEST-containing nuclear protein mediates the proliferation, migration, and invasion of human neuroblastoma cells through MAPK and PI3K/AKT/mTOR signaling pathways
BMC Cancer Open Access 02 May 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout


References
Maris, J.M., Hogarty, M.D., Bagatell, R. & Cohn, S.L. Neuroblastoma. Lancet 369, 2106–2120 (2007).
Maris, J.M. et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N. Engl. J. Med. 358, 2585–2593 (2008).
Hero, B. et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J. Clin. Oncol. 26, 1504–1510 (2008).
Nickerson, H.J. et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J. Clin. Oncol. 18, 477–486 (2000).
Matthay, K.K. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341, 1165–1173 (1999).
Berthold, F. et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 6, 649–658 (2005).
Stacey, S.N. et al. The BARD1 Cys557Ser variant and breast cancer risk in Iceland. PLoS Med. 3, e217 (2006).
Onay, V.U. et al. SNP-SNP interactions in breast cancer susceptibility. BMC Cancer 6, 114 (2006).
Johnatty, S.E. et al. The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case-control and family analysis. Breast Cancer Res. Treat. (in the press).
Vahteristo, P. et al. BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition. Eur. J. Hum. Genet. 14, 167–172 (2006).
Mosse, Y.P. et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930–935 (2008).
Wu, L.C. et al. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat. Genet. 14, 430–440 (1996).
Irminger-Finger, I. & Jefford, C.E. Is there more to BARD1 than BRCA1? Nat. Rev. Cancer 6, 382–391 (2006).
Easton, D.F. et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087–1093 (2007).
Hunter, D.J. et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39, 870–874 (2007).
Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
Price, A.L. et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38, 904–909 (2006).
Patterson, N., Price, A.L. & Reich, D. Population structure and eigenanalysis. PLoS Genet. 2, e190 (2006).
Barrett, J.C., Fry, B., Maller, J. & Daly, M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263–265 (2005).
Acknowledgements
The authors acknowledge the Children's Oncology Group for providing neuroblastoma specimens. M.C. is supported in part by Fondazione Italiana per la Ricerca sul Cancro, FIRC, and K.B. is supported by the Howard Hughes Medical Institute Research Training Fellowship. This work was supported in part by R01-CA124709 (J.M.M.), the Giulio D'Angio Endowed Chair (J.M.M.), the Alex's Lemonade Stand Foundation (J.M.M.), Andrew's Army Foundation (J.M.M.), the Rally Foundation (J.M.M.), the Evan Dunbar Foundation (J.M.M.), the Abramson Family Cancer Research Institute (J.M.M.) and the Center for Applied Genomics (H.H.) at the Joseph Stokes Research Institute.
Author information
Authors and Affiliations
Contributions
M.C., M. Devoto, H.H. and J.M.M. designed the experiment and drafted the manuscript. C.H., E.F.A., Y.P.M., K.A.C., M.L., C.W., M.G., K.B., M. Diamond and C.K. performed sample collection and quality control, and the genome-wide genotyping. W.B.L. identified high-risk neuroblastoma cases and assisted in sample selection. M.C., M. Devoto, J.P.B., S.J.D., J.J., J.T.G., S.F.A.G. and H.L. analyzed SNP data and performed association analyses. J.P.B., H.H., S.F.A.G. and H.L. performed the corrections for population stratification. S.A., R.H.S., R.C.S., C.M. and N.R. performed the BARD1 replication genotyping and analyses. C.H. and E.R. performed the genotyping of potential regulatory SNPs. All authors commented on or contributed to the manuscript.
Corresponding authors
Supplementary information
Supplementary Text and Figures
Supplementary Methods, Supplementary Tables 1–4 and Supplementary Figures 1 and 2 (PDF 674 kb)
Rights and permissions
About this article
Cite this article
Capasso, M., Devoto, M., Hou, C. et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet 41, 718–723 (2009). https://doi.org/10.1038/ng.374
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.374
This article is cited by
-
MYC-associated protein X binding with the variant rs72780850 in RNA helicase DEAD box 1 for susceptibility to neuroblastoma
Science China Life Sciences (2021)
-
p50 mono-ubiquitination and interaction with BARD1 regulates cell cycle progression and maintains genome stability
Nature Communications (2020)
-
Genetic predisposition and chromosome instability in neuroblastoma
Cancer and Metastasis Reviews (2020)
-
HIF-1 transcription activity: HIF1A driven response in normoxia and in hypoxia
BMC Medical Genetics (2019)
-
PEST-containing nuclear protein mediates the proliferation, migration, and invasion of human neuroblastoma cells through MAPK and PI3K/AKT/mTOR signaling pathways
BMC Cancer (2018)